Just playing devil's advocate here, and I will say even I think this is unlikely, but what if the big pharma (presumably Pfizer) that has the CDA in place for Kevetrin has been encouraged enough by the trial so far that they want to take another step forward beyond he CDA?
Again, very unlikely this early in the game, but not outside the realm of possibility. I could envision a limited joint venture of some sort being worked on to help CTIX further expand testing of Kevetrin for different applications.
A few times now we have heard in PRs or interviews from both Leo and Dr Menon the comments that more partnerships are possible as Kevetrin advances into what many of us consider the critical point of the trial where we may start to see some fireworks.
Just speculating out loud, but I have a hard time seeing a Pfizer just sitting on their hands until K is well proven in trials, and someone like a Celgene or Roche steps in to the game and ups the competition to own K significantly.
News 
Market Data 
Discover 
AI
